EUVIMEDEUVIMED entdecken
Open Access

Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study

Avni Madhani iD, Natalia Sabogal iD, Daniel Massillon iD, Ludwine D Paul iD, Carlos Rodriguez, Denise Fine iD, Stephen Helmke iD, Morgan Winburn iD, Damian Kurian iD, Farbod Raiszadeh, Sergio Teruya, Elizabeth Cohn und 5 weitere

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.122.028973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Avni Madhani und 16 weiteren Autor:innen. Beteiligte Einrichtung: Boston University Chobanian & Avedisian School of Medicine Boston MA. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Amyloidosis, Cardiomyopathies, Heart Failure. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an underdiagnosed cause of heart failure (HF) among patients ≥60 years of age. Although the V122I (valine to isoleucine substitution at position 122 of the transthyretin protein) variant associated with hereditary ATTR‐CM is present in 3.4% of self‐identified Black individuals in the United States (or 1.5 million people), the phenotypic penetrance is not known. Methods and Results The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) study is a currently accruing prospective multisite study designed to determine the prevalence of ATTR‐CM using technetium‐99m‐pyrophosphate imaging in older (≥60 years of age) self‐identified Black and Hispanic individuals with HF. Calculations of the penetrance and prevalence of the V122I allele, along with analyses of functional, biochemical, and echocardiographic parameters, were performed for the first 278 Black participants in SCAN‐MP. The prevalence of ATTR‐CM was 6.8% (95% CI, 4.2–10.5; n=19 cases), of whom 63% were ATTR wild‐type. The prevalence of V122I was 6.5% (n=18 carriers), of whom 7 had ATTR‐CM, yielding a phenotypic penetrance of 39% (95% CI, 17–64). V122I carriers with ATTR‐CM evidenced more advanced HF than carriers without ATTR‐CM. Prealbumin concentration was lowest among V122I carriers with ATTR‐CM (12.9 mg/dL) versus carriers without ATTR‐CM (21.0 mg/dL) and HF controls (25.0 mg/dL, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialAmyloidosisCardiomyopathiesHeart FailureAgedHumansHealth Disparate Minority and Vulnerable PopulationsPenetrancePrealbuminProspective Studies

Stichwörter der Autor:innen

amyloidbiomarkerscardiomyopathygeneticsheart failure

Substanzen

PrealbuminTTR protein, human

Autor:innen und Institutionen

  • Boston University Chobanian & Avedisian School of Medicine Boston MA.
  • Section of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center Boston MA.
  • Seymour, Paul, and Gloria Milstein Division of Cardiology, Department of Medicine Columbia University Irving Medical Center, and New York-Presbyterian Hospital New York NY.
  • Division of Cardiology, Harlem Hospital Center New York City Health and Hospital Corporation New York NY.
  • Hunter College, City University of New York New York NY.
  • Department of Radiology Columbia University Irving Medical Center, and New York-Presbyterian Hospital New York NY.

ORCID-Profile: Avni Madhani, Natalia Sabogal, Daniel Massillon, Ludwine D Paul, Denise Fine, Stephen Helmke, Morgan Winburn, Damian Kurian, Andrew J Einstein, Edward J Miller, Mathew S Maurer, Frederick L Ruberg

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Madhani, A., Sabogal, N., Massillon, D., Paul, L. D., Rodriguez, C., Fine, D., Helmke, S., Winburn, M., Kurian, D., Raiszadeh, F., Teruya, S., Cohn, E., Einstein, A. J., Miller, E. J., Connors, L. H., Maurer, M. S., & Ruberg, F. L. (2023). Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.028973

Vancouver

Madhani A, Sabogal N, Massillon D, Paul LD, Rodriguez C, Fine D, et al. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.028973

BibTeX
@article{Madhani2023,
  author = {Madhani, Avni and Sabogal, Natalia and Massillon, Daniel and Paul, Ludwine D and Rodriguez, Carlos and Fine, Denise and Helmke, Stephen and Winburn, Morgan and Kurian, Damian and Raiszadeh, Farbod and Teruya, Sergio and Cohn, Elizabeth and Einstein, Andrew J and Miller, Edward J and Connors, Lawreen H and Maurer, Mathew S and Ruberg, Frederick L},
  title = {Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.122.028973}
}
Kostenlos starten →